Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 871 to 885 of 1235 results for pain

  1. Faecal microbiota transplant for recurrent Clostridioides difficile infection (HTG638)

    Evidence-based recommendations on faecal microbiota transplant for recurrent Clostridioides difficile infection.

  2. Vinflunine for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract (TA272)

    Evidence-based recommendations on vinflunine (Javlor) for treating advanced transitional cell carcinoma of the urothelial tract in adults.

  3. Pemetrexed for the treatment of non-small-cell lung cancer (TA124)

    Evidence-based recommendations on pemetrexed for treating non-small-cell lung cancer in adults.

  4. What are the causative and contributory factors underlying the persistently very low levels of reported patient satisfaction for bladder cancer?

    treated in general wards in hospital and experience significant symptoms of pain and bleeding (haematuria). To explore this research...

  5. Pharmacological therapies:- What is the clinical and cost effectiveness of benzodiazepines for the acute management of low back pain?

    cost effectiveness of benzodiazepines for the acute management of low back pain? Any explanatory notes(if applicable) Why this is...

  6. What is the effectiveness of awake body positioning in improving outcomes for people in hospital with COVID-19 who are not intubated and have higher oxygen needs?

    session)• patient reported outcomes including dyspnoea, anxiety, delirium, pain, discomfort, breathlessness, impact on sleep• mortality•...

  7. Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis (TA1018)

    Evidence-based recommendations on fedratinib (Inrebic) for treating disease-related splenomegaly or symptoms of primary myelofibrosis, post-polycythaemia vera myelofibrosis or post-essential thrombocythaemia myelofibrosis in adults.

  8. Olipudase alfa for treating acid sphingomyelinase deficiency (Niemann–Pick disease) type AB and type B (HST32)

    Evidence-based recommendations on olipudase alfa (Xenpozyme) for treating acid sphingomyelinase deficiency (Niemann–Pick disease) in people with type AB or type B.

  9. Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases (TA412)

    Evidence-based recommendations on radium-223 dichloride (Xofigo) for treating hormone-relapsed prostate cancer with bone metastases in adults.

  10. Narrow band imaging for Barrett's oesophagus (MIB179)

    NICE has developed a medtech innovation briefing (MIB) on narrow band imaging for Barrett’s oesophagus .

  11. Cabozantinib for previously treated advanced hepatocellular carcinoma (TA849)

    Evidence-based recommendations on cabozantinib (Cabometyx) for advanced hepatocellular carcinoma in adults who have had sorafenib.

  12. Minimally invasive oesophagectomy (HTG272)

    Evidence-based recommendations on minimally invasive oesophagectomy. This involves making small cuts or holes in the chest wall and inserting a camera and other instruments into the chest cavity to carry out the operation.

  13. Low-energy contact X-ray brachytherapy for rectal cancer (HTG763)

    Evidence-based recommendations on low-energy contact X-ray brachytherapy for rectal cancer. This involves inserting an X-ray tube through the anus into the rectum. The tube is placed in contact with the tumour and releases a low dose of X-ray radiation (brachytherapy) directly to it.

  14. Pembrolizumab for advanced melanoma not previously treated with ipilimumab (TA366)

    Evidence-based recommendations on pembrolizumab (Keytruda) for treating advanced melanoma in adults who have not had ipilimumab.

  15. ATEC system for vacuum-assisted breast biopsy (MIB43)

    NICE has developed a medtech innovation briefing (MIB) on the ATEC breast biopsy system